Buchumschlag

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: MIF is a pleiotropic cytokine involved in tumor cell proliferation, angiogenesis, and inflammati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mahalingam, Devalingam (VerfasserIn) , Halama, Niels (VerfasserIn) , Jäger, Dirk (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 16 October 2016
In: Annals of oncology
Year: 2016, Jahrgang: 27
ISSN:1569-8041
DOI:10.1093/annonc/mdw368.08
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw368.08
Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/365PD/2799103
Volltext
Verfasserangaben:D. Mahalingam, M.R. Patel, J.C. Sachdev, L.L. Hart, N. Halama, R.K. Ramanathan, J. Sarantopoulos, X. Liu, S. Yazji, D. Jäger, M. Yoon, G.Ç Manzur, D. Adib, R. Kerschbaumer, A. Tsimberidou
Beschreibung
Zusammenfassung:© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: MIF is a pleiotropic cytokine involved in tumor cell proliferation, angiogenesis, and inflammation. oxMIF is the pathogenic isoform found in tumor and its stroma. Imalumab is a novel recombinant, fully human, monoclonal antibody that targets oxMIF, with antitumor activity.Methods: Dose escalation study (3 + 3 design). Primary endpoint was maximum tolerated dose (MTD). Secondary endpoints were antitumor activity, safety, pharmacokinetics (PK), and pharmacodynamics (PD). Patients (pts), previously treated with other agents, received intravenous (IV) imalumab [28-d cycles; 2 dose schedules]: biweekly in all solid tumors (Q2W); weekly in metastatic colorectal cancer (mCRC), metastatic ovarian cancer (OvCa), and metastatic non-small cell lung cancer (NSCLC) (QW).Results: 50 pts dosed on the trial: 19 (Q2W) in 6 cohorts (1, 3, 10, 25, 37.5, and...
Beschreibung:Gesehen am 10.11.2017
Beschreibung:Online Resource
ISSN:1569-8041
DOI:10.1093/annonc/mdw368.08

Ähnliche Einträge